Free Trial

Immunovant (IMVT) Competitors

Immunovant logo
$18.82 -0.08 (-0.42%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IMVT vs. SLNO, VTRS, ROIV, BBIO, MRNA, QGEN, ELAN, VRNA, RVMD, and ABVX

Should you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Soleno Therapeutics (SLNO), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), QIAGEN (QGEN), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), and Abivax (ABVX). These companies are all part of the "medical" sector.

Immunovant vs. Its Competitors

Immunovant (NASDAQ:IMVT) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Immunovant presently has a consensus target price of $28.78, suggesting a potential upside of 52.91%. Soleno Therapeutics has a consensus target price of $115.92, suggesting a potential upside of 80.06%. Given Soleno Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than Immunovant.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunovant
1 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.58
Soleno Therapeutics
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.93

47.1% of Immunovant shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Soleno Therapeutics' return on equity of -73.74% beat Immunovant's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunovantN/A -80.99% -72.23%
Soleno Therapeutics N/A -73.74%-56.67%

In the previous week, Soleno Therapeutics had 12 more articles in the media than Immunovant. MarketBeat recorded 13 mentions for Soleno Therapeutics and 1 mentions for Immunovant. Immunovant's average media sentiment score of 1.03 beat Soleno Therapeutics' score of 0.63 indicating that Immunovant is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immunovant
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Soleno Therapeutics
5 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Immunovant has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.75, indicating that its stock price is 375% less volatile than the S&P 500.

Soleno Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunovantN/AN/A-$413.84M-$2.85-6.60
Soleno TherapeuticsN/AN/A-$175.85M-$4.14-15.55

Summary

Soleno Therapeutics beats Immunovant on 9 of the 13 factors compared between the two stocks.

Get Immunovant News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMVT vs. The Competition

MetricImmunovantMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.28B$3.42B$6.18B$10.68B
Dividend YieldN/A2.24%5.72%4.86%
P/E Ratio-6.6023.2229.6728.51
Price / SalesN/A480.11579.48129.35
Price / CashN/A45.5937.1261.42
Price / Book4.5210.3312.086.53
Net Income-$413.84M-$52.53M$3.32B$276.85M
7 Day Performance8.10%-0.32%-0.31%0.19%
1 Month Performance26.31%10.78%5.71%1.71%
1 Year Performance-37.31%14.14%65.71%33.13%

Immunovant Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMVT
Immunovant
2.2468 of 5 stars
$18.82
-0.4%
$28.78
+52.9%
-36.1%$3.28BN/A-6.60120Positive News
SLNO
Soleno Therapeutics
4.2803 of 5 stars
$64.27
+0.8%
$115.92
+80.4%
+24.7%$3.39BN/A-15.5230
VTRS
Viatris
3.1288 of 5 stars
$9.86
+1.2%
$10.40
+5.5%
-10.8%$11.36B$14.74B-3.4032,000Analyst Forecast
ROIV
Roivant Sciences
2.8749 of 5 stars
$16.21
+1.1%
$19.94
+23.0%
+53.1%$10.95B$29.05M-23.16860
BBIO
BridgeBio Pharma
4.5827 of 5 stars
$55.96
+0.8%
$63.94
+14.3%
+113.5%$10.61B$221.90M-13.68400Analyst Forecast
MRNA
Moderna
4.2628 of 5 stars
$26.74
-0.3%
$41.81
+56.4%
-49.7%$10.48B$3.24B-3.555,800Trending News
Analyst Forecast
Gap Down
QGEN
QIAGEN
4.1075 of 5 stars
$47.30
+1.0%
$49.40
+4.4%
+18.4%$10.41B$1.98B27.955,765
ELAN
Elanco Animal Health
2.7239 of 5 stars
$20.04
+1.4%
$19.14
-4.5%
+70.9%$9.82B$4.44B23.309,000Analyst Forecast
VRNA
Verona Pharma PLC American Depositary Share
1.077 of 5 stars
$106.91
flat
$109.00
+2.0%
N/A$9.21B$42.28M-107.9930Positive News
RVMD
Revolution Medicines
4.2957 of 5 stars
$48.75
+1.1%
$74.64
+53.1%
+12.4%$9.02B$11.58M-10.83250News Coverage
Analyst Upgrade
ABVX
Abivax
3.4857 of 5 stars
$95.63
+2.0%
$114.25
+19.5%
+763.9%$7.30BN/A0.0061Short Interest ↓

Related Companies and Tools


This page (NASDAQ:IMVT) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners